Suchergebnisse - "Myeloma"

PubPharm (39.809)

81

A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments : Phase 1b Study of REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody) Plus Other Cancer Treatments for Patients With Relapsed/Refractory Multiple Myeloma

enthalten in: ClinicalTrials.gov | 2024

82

Fixed Duration vs Continuous Daratumumab in Transplant Ineligible Older Adults With Newly Diagnosed Multiple Myeloma : A Phase III Non-Inferiority Randomized Controlled Trial of Fixed Duration Versus Continuous Daratumumab Among Transplant Ineligible Older Adults With Newly Diagnosed Multiple Myeloma

enthalten in: ClinicalTrials.gov | 2024

83

Communication About Chimeric Antigen Receptor T-Cell (CAR-T) Therapy

enthalten in: Transplantation and cellular therapy | 2024

von Dhawale, T. | Johnson, P. | Boateng, K. | +11

84

Assessment of algorithms for identifying patients with triple-class refractory multiple myeloma using real-world data

enthalten in: Current medical research and opinion | 2024

von Sinyavskaya, L. | Meche, A. | Faucher, A. | +6

85

ASTCT Committee on Practice Guidelines Survey on Evaluation & Management of Relapsed Refractory Multiple Myeloma after Failure of Chimeric Antigen Receptor T-Cell Therapy

enthalten in: Transplantation and cellular therapy | 2024

von Hashmi, H. | Kumar, A. | Kharfan-Dabaja, M. | +10

86

Testing the Addition of Ixazomib/Placebo to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial : Optimizing Prolonged Treatment In Myeloma Using MRD Assessment (OPTIMUM)

enthalten in: ClinicalTrials.gov | 2024

87

Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies : Nivolumab for Relapsed or Refractory Disease Post Chimeric Antigen Receptor T-Cell Treatment in Patients With Hematologic Malignancies

enthalten in: ClinicalTrials.gov | 2024

88

Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma : A Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma

enthalten in: ClinicalTrials.gov | 2024

89

Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant : A RANDOMIZED, 2-ARM, PHASE 3 STUDY OF ELRANATAMAB (PF-06863135) VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEM-CELL TRANSPLANTATION

enthalten in: ClinicalTrials.gov | 2024

90

A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2) : A Phase 3, Two-stage, Randomized, Multicenter, Open-label Study Comparing Mezigdomide (CC-92480/BMS-986348), Carfilzomib, and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM): SUCCESSOR-2

enthalten in: ClinicalTrials.gov | 2024